Centiva Capital’s Integra LifeSciences IART Stock Holding History

Centiva Capital’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,174	Closed	-$162K	–	1437
2025 Q2	$162K	Buy	13,174 +495	+4%	+$7.19K	﹤0.01%	1370
2025 Q1	$279K	Buy	+12,679	New	+$298K	0.01%	1121
2024 Q4	–	Sell	-10,561	Closed	-$192K	–	2002
2024 Q3	$192K	Buy	+10,561	New	+$245K	﹤0.01%	1838
2024 Q1	–	Sell	-16,534	Closed	-$720K	–	1969
2023 Q4	$720K	Buy	+16,534	New	+$651K	0.02%	777
2023 Q3	–	Sell	-13,276	Closed	-$546K	–	1871
2023 Q2	$546K	Buy	+13,276	New	+$639K	0.01%	790

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's IART Position: Q3 2025 in Review

Centiva Capital sold out of Integra LifeSciences (IART) in Q3 2025, closing a stake of 13,174 shares — an estimated $162K sold.

Centiva Capital first reported a position in IART in Q2 2023 and held it in 5 quarters. The position peaked at $720K in Q4 2023. 207 funds tracked by Wall St. Rank hold IART as of Q3 2025.

Centiva Capital reported no remaining Integra LifeSciences position as of Q3 2025 after selling out during the quarter.
Centiva Capital sold 13,174 Integra LifeSciences shares in Q3 2025, an estimated $162K.
Centiva Capital first reported a position in Integra LifeSciences in Q2 2023 and held it in 5 quarters.
Centiva Capital's Integra LifeSciences position peaked at $720K in Q4 2023.
207 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.